ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

WX

45.90
0.00 (0.00%)
31 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
NYSE:WX NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 45.90 0.00 01:00:00

Dr. Ge Li Receives Executive of the Year Award from SCRIP

07/12/2015 1:00pm

PR Newswire (US)


(NYSE:WX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more  Charts.

SHANGHAI, Dec. 7, 2015 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that Dr. Ge Li, WuXi's Chairman and CEO, was named Executive of the Year at the 11th annual SCRIP Awards on December 2 in London.  Established by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech industry, the annual SCRIP Awards recognize the industry's highest achievements by both companies and individuals across the value chain.

Dr. Li was recognized for his vision in building an open-access R&D capability and technology platform to help advance innovative medicines more efficiently and cost effectively.  Under his exemplary leadership, WuXi platform is enabling the efforts of more than 2,000 collaborative partners worldwide and contributing to breakthrough therapies that are profoundly improving patients' lives.  

"I am deeply honored and inspired by this award," said Dr. Li.  "I would like to thank our many customers and partners for their tremendous support for our efforts.  It has been our great privilege to help bring some of the most innovative healthcare products closer to patients."

About WuXi PharmaTech

WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process.  WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge (for investors)
LaVoieHealthScience
+1 617-374-8800 x109 
+1 617-792-2459 
ron_aldridge@wuxiapptec.com  

Aaron Shi (for media)
Director, Corporate Communications
WuXi PharmaTech 
+86-21-5046-4362
aaron_shi@wuxiapptec.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-ge-li-receives-executive-of-the-year-award-from-scrip-300188585.html

SOURCE WuXi PharmaTech (Cayman) Inc.

Copyright 2015 PR Newswire

1 Year Chart

1 Year  Chart

1 Month Chart

1 Month  Chart

Your Recent History

Delayed Upgrade Clock